Sign in
SuspendedPhase 3

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

Key facts

Who runs it
Galmed Research and Development, Ltd.
Where
Arlington and Miami, United StatesSee the 2 sites
Trial code
Status
Suspended
Phase
Phase 3
People taking part
157 people enrolled
Started
23 Sept 2019
Expected to end
30 Jun 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Aramchol free acid
  • Placebo
Record updated
11 February 2026
Why it stopped
Interim analysis results from the open-label part of the study. The double blind portion of the study will be resumed once the study will continue.

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Male or female age 18 to 75 years
  • Histological confirmation of NASH on a diagnostic liver biopsy by central reading of the slides (biopsy obtained within 6 months prior to randomization or during the screening period)
  • Total NAS Score 4 or more with at least 1 in each component of the NAS Score (steatosis ≥1 AND inflammation ≥1 AND ballooning ≥1)
  • Fibrosis Stage must be 2 or 3 (Open-Label Part may include up to 30 subjects with fibrosis stage 1)
  • Body mass index (BMI) between 25kg/m2 and 40 kg/m2 (Open Label part: BMI <40 kg/m2)
  • AST>20 IU/L
  • Type 2 diabetes mellitus or prediabetes (Open Label Part only: Type 2 diabetes or prediabetes is not an inclusion criteria)
  • For subjects with type 2 diabetes, glycemia must be controlled
  • Females of childbearing potential must practice a highly effective method of contraception throughout the study period and for 1 month after treatment discontinuation
  • Able to understand the nature of the study and to provide signature of the written informed consent

Who cannot take part

  • Prior history or presence of decompensated liver disease
  • Known alcohol and/or any other drug abuse or dependence in the last five years
  • Weight loss of more than 5% within 3 months prior to screening
  • Treatment with drugs that may cause NAFLD within 12 months prior to liver biopsy
  • Treatment with some anti-diabetic medications; Unless started prior to biopsy (timeframe depending on drug) and stable
  • Current or planned treatment with immunosuppressive drugs
  • Model for End-Stage Liver Disease (MELD) score > 12
  • Other (acute or chronic) coexisting liver disease based on medical history and/or centralized review of liver histology)
  • History of bariatric surgery within 5 years of liver biopsy or planned surgery for weight reduction
  • Evidence of any other unstable or untreated clinically significant disease
  • Uncontrolled hypertension
  • Any other condition that in the opinion of the Investigator warrants exclusion from the study
  • ALT or AST >5× upper limit of normal (ULN)
  • Platelet count < 150,000mm3
  • Alkaline phosphatase ≥2× ULN
  • Histologically documented liver cirrhosis (fibrosis stage 4)
  • Inability or unwillingness to undergo a liver biopsy
  • Abnormal synthetic liver function
  • Known or suspected hepatocellular carcinoma (HCC)

Where in United States

  • Texas Clinical Research Institute, LLCArlington, United States
  • The Public Health Trust of Miami-Dade County, Florida, dba the Jackson Health SystemMiami, United States

About the trial

What the trial wants to find out

An Open-Label Part was added:

Read full original descriptionShow less

This part will enroll in selected sites which are less affected by the COVID-19 pandemic.

150 subjects with NASH and fibrosis confirmed by liver histology (F1-F3) will be randomized into 3 groups according to the post-baseline biopsy.

The objective of the Open-Label Part is:

* To evaluate the safety and PK of twice daily administration (BID) of Aramchol 300mg in subjects with NASH and liver fibrosis. * To explore the kinetics of histological outcome measures and Non-Invasive Tests (NITs) associated with NASH and fibrosis for the treatment duration of 24, 48 and 72 weeks.

All patients will be allocated to Aramchol.

Double Blind Part:

This part is double blind, placebo controlled randomized in subjects with NASH and fibrosis stages 2-3 who are overweight or obese and have prediabetes or type 2 diabetes.

The primary objectives of this part of the study are to evaluate the effect of Aramchol as compared to placebo on NASH resolution, fibrosis improvement and clinical outcomes related to progression of liver disease.

Subjects will be randomized to receive Aramchol 300mg BID or matching placebo in a 2:1 randomization ratio.

This double-blind phase of the study will recruit patients once the study will be continued.

The 2 groups in the trial

  • Aramchol free acidTreatment being tested

    Aramchol 300 mg oral tablet

  • PlaceboPlacebo, for comparison

    Placebo matching oral tablet

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy PK, Kinetics and Safety of Aramchol in Nonalcoholic Steatohepatitis (NASH) With Open-Label Part
Publications
Record updated
11 February 2026